Search Login Register

Anistreplase (APSAC) Summary

Description: An acylated inactive complex of streptokinase and human lysine-plasminogen. After injection, the acyl group is slowly hydrolyzed, producing an activator that converts plasminogen to plasmin, thereby initiating fibrinolysis. Its half-life is about 90 minutes compared to 5 minutes for TPA; (TISSUE PLASMINOGEN ACTIVATOR); 16 minutes for UROKINASE-TYPE PLASMINOGEN ACTIVATOR and 23 minutes for STREPTOKINASE. If treatment is initiated within 3 hours of onset of symptoms for acute myocardial infarction, the drug preserves myocardial tissue and left ventricular function and increases coronary artery patency. Bleeding complications are similar to other thrombolytic agents.

Also Known As: APSAC; Anisoylated Plasminogen-Streptokinase Activator Complex; BRL-26921; Eminase; Iminase Show All >>

Networked: 227 relevant articles (25 outcomes, 79 trials/studies) for this Drug

Key Diseases for which Anistreplase is Relevant

  1. Myocardial Infarction : 13 outcomes 72 studies in 175 results
  2. Thrombosis (Thrombus) : 3 outcomes 1 study in 16 results
  3. Infarction : 3 outcomes 1 study in 16 results
  4. Pain (Aches) : 2 outcomes 1 study in 8 results
  5. Hemorrhage : 2 outcomes in 20 results
Show All >>

Drugs Related to Anistreplase

  1. Anistreplase (APSAC)
  2. Streptokinase
  3. Tissue Plasminogen Activator (Alteplase)
  4. Fibrinolytic Agents (Antithrombotic Agents)
  5. Heparin (Liquaemin)
  6. Plasminogen
  7. Urokinase-Type Plasminogen Activator (Urokinase)
  8. Fibrin
  9. streptokinase-plasminogen complex
  10. Fibrinogen (Factor I)
Show All >>

Therapies Related to Anistreplase

  1. Intravenous Infusions
  2. Intravenous Injections
  3. Thrombolytic Therapy
  4. Angioplasty (Angioplasty, Transluminal)
  5. Aftercare (After-Treatment)
Show All >>

CureHunter Inc. provides medical information and specifically does NOT provide medical advice.
© Copyright 2003-2016 CureHunter Inc., MeSH copyright NLM, Journal Articles copyright original owners.